The Korean government has announced its intention to become the world’s No. 1 biopharmaceutical powerhouse by 2030 by attracting 15.7 trillion won in private investment and providing related support under the Bioeconomy 2.0 Initiative.At the Bioeconomy 2.0 Roundtable held at the Seoul BioHub on July
Elliott Management, a U.S.-based private equity fund, criticized the South Korean government’s decision to file an appeal lawsuit against an international investment dispute decision, saying that “the rejection of the decision sends the wrong message that South Korea is tolerant of corruption.” The
SK Co., Ltd. announced on July 18 that it had selected Brain Asset Management as the preferred negotiating partner for capital raising (pre-IPO) of its contract development and manufacturing organization (CDMO) subsidiary SK pharmteco. The scale of the investment attraction is around 500 million dol
Korea has ranked third in Asia in the global biopharma resilience index rankings in 2023. This represented a drop of two notches from 2021 when the COVID-19 pandemic was rampant. In the global rankings of 22 countries, Korea dropped sharply from 7th place to 12th over the same period. The decline wa
Samsung Electronics has slipped to fourth place in global semiconductor market capitalization rankings, surpassed by U.S.-based fabless semiconductor firm Broadcom. Non-memory companies such as Nvidia and Broadcom are expanding their territories through massive investments and mergers and acquisitio
“Huawei is willing to share cutting-edge innovations in the form of patents with the world,” said the company’s Chief Legal Officer, Song Liuping, who added, “These will support the common, sustainable development of industries globally.”His remarks were made at Huawei’s annual flagship event on inn
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company’s CEO, Jaeyong Ahn has virtually participated as a panelist in the academic workshop session of ‘Pandemic Product Research and Development: Insights from P
GC Biopharma’s and SK plasma’s entries into Indonesia will accelerate this year. GC Biopharma is expected to finalize all procedures within this year after receiving approval for business rights related to the construction of a blood product factory and a technology transfer from the Indonesian gove
Korean President Yoon Suk-yeol’s upcoming visit to Poland has raised expectations that Korean companies will be able to gain an edge in the second phase of Poland’s nuclear power plant project if the two countries strengthen cooperation in the field of green energy.After failing to win the first pha
A three-dimensional (3D) bioprinting technology capable of eliminating cancer cells using the function of immune cells has been developed for the first time in the world.Through joint research with the Korea Institute of Machinery and Materials (President Sang Jin Park, hereinafter referred to as KI
The K-Ricebelt initiative, aimed at increasing rice production in Africa by disseminating Korean rice seeds and agricultural technology, has officially begun.The Ministry of Agriculture, Food and Rural Affairs held the K-Ricebelt Ministerial Meeting at the JW Marriott Hotel in the Seocho district of
New investments in venture startups plunged by one third in the first half of the year. The number of startups that received big investments plummeted.According to startup investment information platform TheVC, startups and SMEs received 2.819 trillion won (US$2.160 billion) in investment in the fir
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Although SK Biopharm’s operating losses likely narrowed q-q in 2Q23, we believe that COGS-to-sales ratio returned to the previous high level, and SG&A expenses likely upped q-q on clinical costs. How
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has signed a Memorandum of Understanding (MOU) with the Government Pharmaceutical Organization (GPO), a state pharmaceutical enterprise in Thailand, to str
Huawei announced they will launch a complete set of commercial 5.5G network equipment in 2024 at the 5G Advanced Forum during MWC Shanghai 2023. Huawei's Director and President of ICT Products & Solutions Yang Chaobin who made the announcement said the company intends for this launch to mark the
Nine merger and acquisition (M&A) deals worth more than US$1 billion were made in the global pharmaceutical and bio industries in the first half of this year.According to the Korea Biotechnology Industry Organization (KBIO) on July 2, the global pharmaceutical and bio industries recorded nine M&A de
On July 1 (local time), the U.S. Humira biosimilar market, worth 24 trillion won a year, opened. In the first week alone, six Korean and foreign companies plan to launch their products.According to sources in the biotech industry on July 2, Samsung Bioepis launched Hadlima, a Humira biosimilar, in t
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, ‘GBP410’ (also known as SP0202), evaluating i
Huawei has shown up in full force for MWC Shanghai 2023, with their activities all falling under their theme of "GUIDE to the Intelligent World". This year, the company's activities include an experiential tour that takes audiences to multiple cities to learn about their technology and business,
At the opening day of MWC Shanghai 2023 today, Sabrina Meng, Huawei's Rotating Chairwoman and CFO, gave a keynote outlining the value that 5G has generated throughout its first four years of commercial use.“5G is already well on its way to driving business success,” said Meng. “It's transfor